Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag367 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Stuart Byrne und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Respiratory Syncytial Virus, Human. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd.
Abstract (Originalsprache)
Background
S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model.
Methods
Healthy adults aged 18–55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2–12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set. Safety was assessed in all randomized participants. Dose-response was evaluated across a wide dose range (1–300 mg).
Results
Of 114 randomized participants, 60 comprised the ITT-I set. Covariate-adjusted mean viral load area under the curve (VL-AUC) was significantly lower in the 30- and 300-mg groups by qRT-PCR (64.87% and 88.94% reductions, respectively, both P < .05) and by viral culture assay (72.32% and 86.17% reductions, respectively, both P < .05). Total symptom score AUC was 78.15% lower in the 300-mg group (P < .05). S-337395 was well-tolerated without any safety concerns.
Conclusions
S-337395 significantly reduced viral load, viral titer, and symptoms, and was well-tolerated in this human challenge study. Clinical Trial Registration: ISRCTN24865912.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
- Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
- Medical Science Department, Shionogi B.V., London, England, United Kingdom.
- Clinical Sciences Department, hVIVO Services Limited, London, England, United Kingdom.
- hSite Medical Operations, hVIVO Services Limited, London, England, United Kingdom.
ORCID-Profile: Takamichi Baba, Nao Kawaguchi, Atsuko Yamamoto, Alex Mann, Takeki Uehara
Förderung
- Shionogi & Co., Ltd
Zitieren
APA
Byrne, S., Baba, T., Kawaguchi, N., Yamamoto, A., Nakano, Y., Dorrepaal, C., Londt, B., Mann, A., Veselinski, N., & Uehara, T. (2026). Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag367
Vancouver
Byrne S, Baba T, Kawaguchi N, Yamamoto A, Nakano Y, Dorrepaal C, et al. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag367
BibTeX
@article{Byrne2026,
author = {Byrne, Stuart and Baba, Takamichi and Kawaguchi, Nao and Yamamoto, Atsuko and Nakano, Yoshiyuki and Dorrepaal, Caroline and Londt, Brandon and Mann, Alex and Veselinski, Nikolay and Uehara, Takeki},
title = {Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag367}
}
EUVIMED